Navigation Links
Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Date:10/27/2009

o-inflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal-Onset Multisystem Inflammatory Disease (NOMID). Rilonacept has not been studied in patients with NOMID.

CAPS are characterized by life-long, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue. Intermittent, disruptive exacerbations or flares can be triggered at any time by exposure to cooling temperatures, stress, exercise, or other unknown stimuli.

CAPS are generally caused by autosomal-dominant mutations (changes) in the NLRP-3 (previously known as CIAS1) gene and resultant alterations in the protein, cryopyrin, which it encodes. Cryopyrin, active in circulating, infection-fighting, white blood cells, controls the production of a protein called interleukin-1 (IL-1). As part of the body's infection-fighting defense system, IL-1 circulates throughout the body and can trigger inflammatory reactions when it binds to inflammatory cells. Researchers have found that alterations in the cryopyrin protein lead to over-production of IL-1, resulting in an inflammatory response and the symptoms of CAPS. Most, but not all, patients with CAPS have the NLRP-3 gene mutation.

The incidence of CAPS has been estimated to be approximately 1 in 1,000,000 people in the European Union.

About Rilonacept

Rilonacept is a targeted inhibitor of interleukin-1 (IL-1), the key driver of inflammation in Cryopyrin-Associated Periodic Syndromes (CAPS). In the pivotal clinical development program for rilonacept, change in disease activity was measured using a composite patient-reported symptom score composed of a daily evaluation of rash, feelings of fever/chills, joint pain, eye redness/pain, and fatigue. Patients treated with rilonacept experienced an improvement in overall symptom scores as compared with patients treated with placebo. These improvements were sustained over time with continued treatment with rilonacept.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
2. Peripheral Artery Disease (PAD) Patent Granted to Dimera
3. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
4. Delcath Systems Granted Third Orphan Drug Designation
5. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
8. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
9. VIASPACE Granted US Patent
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Histogen, Inc., a regenerative medicine ... cells grown under simulated embryonic conditions, will present ... for melanoma during the 2015 Society of Investigative ... 2015 in Atlanta, GA. , Histogen has previously ... material with anti-oncologic properties, with potential benefit in ...
(Date:5/6/2015)... The Remedy Group , the premier provider ... pharmacy industry, will be exhibiting, presenting, and is a ... The Summit will be held May 4-8, 2015 at ... largest annual gathering for the specialty pharmacy industry. Thousands ... pharma/biotech manufacturers, and payers, to learn more about the ...
(Date:5/5/2015)... Mass. , May 5, 2015  Blueprint ... closing of its initial public offering of 9,367,708 ... price of $18.00 per share, including shares of ... the underwriters of their option to purchase additional ... offering to Blueprint Medicines were approximately $168.6 million, before ...
(Date:5/5/2015)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens,  today announced that Paul G. Thomas ... 2015 Health Care Conference on May 12 at 8:00am PT. ... Las Vegas NV. ... the investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... , Michael Su, M.S. and Jin Liao, M.D., Ph.D., ... Molecular Devices Corporation, 8/00 , , INTRODUCTION ... pyralis) is very popular foruse in Reporter Gene Assays. The enzyme ... (Figure 1) 1 . When luciferase is the limiting component in ...
... Michael Su, M.S., ... 8/00 , , INTRODUCTION , ... dilutions of samples were necessary to ensure that they fell ... with greatly improved sensitivity and dynamic range, have become commercially ...
... , ... INTRODUCTION , Adenosine triphosphate (ATP) is present ... can be used as a indicator of viable cell number.ATP measurements ... contamination in the food, drug, health care and personalhealthcare industries, as ...
Cached Biology Technology:Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38) 2Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38) 3Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38) 4High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41) 2High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41) 3ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40) 2ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40) 3ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40) 4
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... HILL As vast and far-reaching as the worlds oceans ... to a study in the journal Science by researchers at ... The international team of scientists integrated global data from ... warming that threaten 20 different marine ecosystems, such as ...
... Ariz. -- If we wanted to create the ideal environmentally ... easy and economical to produce, and one that does not ... at Arizona State University intend to develop in a new ... clean fuel that produces no greenhouse gases. The ...
... 2008, 10 a.m.The Nanoscale Science, Engineering, and ... and Technology Council,s Committee on Technology ... Nanotechnology Initiatives (NNI) strategy for addressing priority ... (EHS) aspects of nanomaterials. The full ...
Cached Biology News:First map of threats to marine ecosystems shows all the world's oceans are affected 2Project focuses on production of hydrogen from bacteria and sunlight 2Project focuses on production of hydrogen from bacteria and sunlight 3Project focuses on production of hydrogen from bacteria and sunlight 4Strategy for nanotechnology-related environmental, health and safety research 2
Quantibody Human Angiogenesis Array 1 (1 slide) Class: Quantitative Antibody Arrays Product Group: Antibody Array...
BD IMagnet 1 each...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
... MW: 34.2kDa Formulation: 10mM HEPES, pH ... dithiothreitiol with 50% glycerol Properites: For ... Certificate of Analysis for individual lots ... followed by gel filtration and Mono-S ...
Biology Products: